New Data on BCMA-Directed Bispecifics in Multiple Myeloma
Promising data on new B-cell maturation antigen (BCMA)-directed bispecific antibodies were presented at the American Society of Clinical Oncology (ASCO) annual meeting. These included results on two investigational products: the phase II LINKER-MM1 study, which showed that linvoseltamab elicited an objective response rate of 71% at the recommended dose of 200 mg for patients with […]